Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inrhythm
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: InCarda Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2022